
    
      This clinical study is designed as a prospective, open-label, single arm, multicenter study
      to evaluate the clinical efficacy and safety of combination Nimotuzumab with concurrent
      radiochemotherapy in children with newly diagnosed diffuse intrinsic pontine glioma(DIPG).
      The main endpoint is objective response rate, 1-year overall survival rate is also observed.
    
  